Zivo Bioscience AI Stock Analysis
Want to see ZIVO full AI Analyst Report?
Zivo Bioscience (ZIVO) AI Stock Analysis
Zivo Bioscience
(Other OTC:ZIVO)
Zivo Bioscience faces significant financial challenges, including negative equity and cash flow issues, which are the primary factors in its low score. Despite some technical indicators showing neutrality, the company's negative valuation metrics further impact the score. Urgent financial restructuring is necessary for sustainability.
Zivo Bioscience (ZIVO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $22.40M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,037
- Price to Earnings (P/E)
- -4.8
- Beta (1Y)
- 0.47
- Revenue Growth
- -100.00%
- EPS Growth
- 47.24%
- Country
- US
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Zivo Bioscience Business Overview & Revenue Model
Company Description
ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufactur...
How the Company Makes Money
Zivo Bioscience makes money by developing and licensing its proprietary algal bioactive compounds to companies in the nutrition, wellness, and animal health industries. The company's revenue streams largely consist of licensing fees, royalties, and c...
Zivo Bioscience Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIVO, the sentiment is Neutral. The current price of 5.76 is below the 20-day moving average (MA) of 7.01, above the 50-day MA of 5.27, and above the 200-day MA of 5.32, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 45.69 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ZIVO.
Zivo Bioscience Risk Analysis
Zivo Bioscience disclosed 26 risk factors in its most recent earnings report. Zivo Bioscience reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksZivo Bioscience Peers Comparison
Overall Rating
PASG46Neutral
CTXR43Neutral
JSPR42Neutral
PTN41Neutral
ZIVO33.5Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $13.68M | -0.41 | -377.94% | ― | ― | 28.49% | |
| 43Neutral | $14.69M | -0.25 | -67.15% | ― | ― | 57.48% | |
| 42Neutral | $15.17M | -0.29 | -618.87% | ― | ― | 73.74% | |
| 41Neutral | $11.10M | -1.19 | -115.00% | ― | ― | ― | |
| 34Underperform | $22.40M | -4.84 | 133.19% | ― | -100.00% | 47.24% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ZIVO | Zivo Bioscience | 5.76 | -6.14 | -51.60% | |
| PTN | Palatin Technologies, Inc. | 6.23 | -6.50 | -51.06% | |
| CTXR | Citius Pharma | 0.54 | -0.40 | -42.78% | |
| PASG | Passage Bio, Inc. | 4.25 | -4.73 | -52.67% | |
| JSPR | Jasper Therapeutics, Inc. | 13.68 | -40.02 | -74.52% |
Zivo Bioscience Corporate Events
Zivo Bioscience CFO Resigns, Interim Successor Appointed
NegativeOn December 19, 2025, Zivo Bioscience’s Chief Financial Officer, Keith R. Marchiando, resigned effective immediately and agreed to end his employment with the company on December 31, 2025, under a separation agreement that provides him with his curre...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Feb 01, 2025
